Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: A randomised controlled trial

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 579-588

  Bodzenta Lukaszyk, Anna ^a   Van Noord, Jan ^b   Schröder Babo, Winfried ^c   McAulay, Kirsten ^d   McIver, Tammy ^d  

^a Uniwersytet Medyczny W Biatymstoku   (Poland)

^b Zuyderland Medical Centre   (Netherlands)

^c Lungen U Bronchialheilkunde Allergologe Gelnhausen Hessen ^*  (United Kingdom)

^d Mundipharma Research Limited   (United Kingdom)

Author keywords

Asthma; Combination therapy; Fluticasone propionate; Formoterol fumarate; ICS LABA

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE;

ADULT; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84876246036     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.772506     Document Type: Article

References (22)

1. GINA Report: Global Strategy for Asthma Management and Prevention. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011. Available at: http://www.ginasthma.org/[last accessed June 2011]
2. Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;5:CD005535. DOI: 10.1002/14651858.CD005535.pub2
3. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;4:CD003137. DOI: 10.1002/14651858. CD003137.pub3
4. Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001;164:923-32
5. Horvath G, Mendes ES, Schmid N, et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol 2007;120:1103-9
6. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587-95
7. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005;99:1263-7
8. Marceau C, Lemiere C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006;118:574-81
9. Shepherd J, Rogers G, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008;12:iii-iv, 1-360
10. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988-92
11. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6(Suppl 16):5-40
12. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. In ATS/ERS Task Force: Standardisation of Lung Function Testing. Series No 2. Eds. Brusasco V, Crapo R, Viegi G. Eur Respir J 2005;26:319-38
13. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2
14. Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; 4:CD003135. DOI: 10.1002/14651858.CD003134.pub4
15. Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; 4:CD003534. DOI: 10.1002/14651858.CD3534.pub3
16. Adams N, Lasserson TJ, Cates CJ, et al. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007;4:CD002310. DOI: 10.1002/14651858.CD002310.pub4
17. Ketchell RI, Jensen MW, Lumley P, et al. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 50-monophosphate in mild asthma. J Allergy Clin Immunol 2002;110:603-6
18. Luijk B, Kempsford RD, Wright AM, et al. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004;23:559-64
19. AstraZeneca UK Ltd: Symbicort Turbohaler Summary of Product Characteristics. website: www.medicines.org.uk/emc/medicine/4821 [last accessed June 2011]
20. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51
21. Harding G, Leidy NK, Meddis D, et al. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin 2009;25:1563-71
22. Bodzenta-Lukaszyk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011;11:28